NATHBIOGEN

Nath Bio-Genes (India) Share Price

 

 

Start SIP in NATHBIOGEN

Start SIP

Performance

  • Low
  • ₹156
  • High
  • ₹162
  • 52 Week Low
  • ₹138
  • 52 Week High
  • ₹239
  • Open Price₹162
  • Previous Close₹162
  • Volume14,143

Investment Returns

  • Over 1 Month + 0.76%
  • Over 3 Month -5.79%
  • Over 6 Month -25.1%
  • Over 1 Year -16.08%

Smart Investing Starts Here Start SIP with Nath Bio-Genes (India) for Steady Growth!

Invest Now

Nath Bio-Genes (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 6.7
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 298
  • P/B Ratio
  • 0.4
  • Average True Range
  • 5.37
  • EPS
  • 21.74
  • Dividend Yield
  • 1.3
  • MACD Signal
  • -2.27
  • RSI
  • 51.39
  • MFI
  • 59.81

Nath Bio-Genes (India) Financials

Nath Bio-Genes (India) Technicals

EMA & SMA

Current Price
₹156.72
-4.79 (-2.97%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹154.89
  • 50 Day
  • ₹159.37
  • 100 Day
  • ₹165.69
  • 200 Day
  • ₹172.72

Resistance and Support

158.4 Pivot Speed
  • R3 167.30
  • R2 164.89
  • R1 160.81
  • S1 154.32
  • S2 151.91
  • S3 147.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nath Bio Genes India has an operating revenue of Rs. 416.39 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 11% is healthy, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 48 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 66 indicates it belongs to a poor industry group of Agricultural Operations and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nath Bio-Genes (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-07-11 Quarterly Results
2025-04-29 Audited Results & Final Dividend
2025-01-23 Quarterly Results
2024-10-23 Quarterly Results
Date Purpose Remarks
2025-08-14 FINAL Rs.2.00 per share(20%)Final Dividend
2024-08-09 FINAL Rs.2.00 per share(20%)Final Dividend
View Nath Bio-Genes (India) Dividend History Arrow

Nath Bio-Genes (India) F&O

Nath Bio-Genes (India) Shareholding Pattern

45.6%
0.76%
0.32%
0%
33.78%
19.54%

About Nath Bio-Genes (India)

  • NSE Symbol
  • NATHBIOGEN
  • BSE Symbol
  • 537291
  • Managing Director
  • Mr. Satish Kagliwal
  • ISIN
  • INE448G01010

Similar Stocks to Nath Bio-Genes (India)

Nath Bio-Genes (India) FAQs

Nath Bio-Genes (India) share price is ₹156 As on 28 December, 2025 | 03:00

The Market Cap of Nath Bio-Genes (India) is ₹297.8 Cr As on 28 December, 2025 | 03:00

The P/E ratio of Nath Bio-Genes (India) is 6.7 As on 28 December, 2025 | 03:00

The PB ratio of Nath Bio-Genes (India) is 0.4 As on 28 December, 2025 | 03:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23